



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	Anti-HIV-1 gp120 Hybridoma (902)
<b>Catalog Number:</b>	521
<b>Lot Number:</b>	110192
<b>Release Category:</b>	C
<b>Provided:</b>	5 x 10 <sup>6</sup> cells/vial. Viability is 93%.
<b>Propagation Medium:</b>	RPMI 1640 supplemented with 200 U/ml penicillin, 2 mM L-glutamine, 0.05 mM β-mercaptoethanol, 90%; fetal bovine serum, 10%.
<b>Freeze Medium:</b>	Propagation medium, 40%; fetal bovine serum, 50%; DMSO, 10%.
<b>Growth Characteristics:</b>	Important: Please see cell culture propagation instructions attached to data sheet. Cells grow in suspension with some adherent cells. Growth is rapid. Doubling time is 24 hours. Split every 3-4 days.
<b>Description</b>	[BIO.A(2R) x A.BY]F1 mouse spleen cells x NS-1. <a href="#">Thawing and Propagation of Hybridomas</a>
<b>Special Characteristics:</b>	Produces an IgG <sub>1</sub> κ monoclonal antibody ( <a href="#">Catalog #522</a> ) which reacts with HIV-1 <sub>LAJ</sub> /HTLV-III <sub>B</sub> gp120 in immunoprecipitation and Western blot assays. Neutralizes infectivity and reacts with cells expressing the envelope proteins of these strains. Binds to the immunodominant hypervariable loop of gp120 (unpublished results). Does not recognize other HIV-1 strains. Mice were immunized via tail scratch with a vaccinia virus expressing gp160. Three-five weeks later, mice received two intraperitoneal inoculations with the same virus. Three days after the second inoculation, mouse spleen cells were fused with NS-1 cells.
<b>Sterility:</b>	Negative for bacteria, fungi, and mycoplasma.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Recommended Storage:** Liquid nitrogen.

**Contributor:** Dr. Bruce Chesebro.

**References:** Chesebro B, Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. *J Virol* **62**:3779-3788, 1988.

Pincus S, Wehrly K, Chesebro B. Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. *J Immunol* **142**:3070-3075, 1989.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Hybridoma (902) from Dr. Bruce Chesebro." Also include the references cited above in any publications.

**Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NIH Office of Technology Transfer, Email: [NIAIDAIDSReagent@niaid.nih.gov](mailto:NIAIDAIDSReagent@niaid.nih.gov), before the reagent can be released. Please specify the name and a description of the intended use of the reagent.**

**Last Updated** September 20, 2016

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.